Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics

Katelyn M Gostic[1], Rebecca Bridge[2], Shane Brady[2], Cécile Viboud[3], Michael Worobey[4], and James O Lloyd-Smith[1,3*]

[1]Dept. of Ecology and Evolutionary Biology, University of California, Los Angeles, Los Angeles, CA, USA
[2]Arizona Department of Health Services, Phoenix AZ, USA
[3]Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
[4]Dept. of Ecology and Evolutionary Biology, University of Arizona, Tucson, AZ, USA
* jlloydsmith@ucla.edu

Abstract

Across decades of co-circulation in humans, influenza A subtypes H1N1 and H3N2 have caused seasonal epidemics characterized by different age distributions of infection and mortality. H3N2 causes the majority of cases in high-risk elderly cohorts, and the majority of overall deaths, whereas H1N1 causes incidence shifted towards young and middle-aged adults, and fewer deaths. These contrasting age profiles may result from differences in childhood exposure to H1N1 and H3N2 or from differences in evolutionary rate between subtypes. Here we analyze a large epidemiological surveillance dataset to test whether childhood immune imprinting shapes seasonal influenza epidemiology, and if so, whether it acts primarily via immune memory of a particular influenza subtype or via broader immune memory that protects across subtypes. We also test the impact of evolutionary differences between influenza subtypes on age distributions of infection. Likelihood-based model comparison shows that narrow, within-subtype imprinting is the strongest driver of seasonal influenza risk. The data do not support a strong effect of evolutionary rate, or of broadly protective imprinting that acts across subtypes. Our findings emphasize that childhood exposures can imprint a lifelong immunological bias toward particular influenza subtypes, and that these cohort-specific biases shape epidemic age distributions. As a result, newer and less "senior" antibody responses acquired later in life do not provide the same strength of protection as responses imprinted in childhood. Finally, we project that the relatively low mortality burden of H1N1 may increase in the coming decades, as cohorts that lack H1N1-specific imprinting eventually reach old age.

Introduction

Childhood influenza exposures leave an immunological imprint, which has reverberating, lifelong impacts on immune memory. Foundational work on original antigenic sin (1) and antigenic seniority (2) showed that individuals maintain the highest antibody titers against influenza strains encountered in childhood. But how these serological patterns map to functional immune protection, and shape birth year-specific risk during outbreaks, remains an active area of inquiry. One open question is the breadth of cross-protection provided by immune memory imprinted by influenza viruses encountered in childhood.

Many epidemiological studies highlight benefits from imprinting protection; every modern influenza pandemic has spared certain birth cohorts, presumably due to cross-protective memory primed in childhood (3–9). Recently, we showed that childhood imprinting also protects against novel, emerging avian influenza viruses (8,10). Childhood imprinting may additionally shape birth year-specific risk from seasonal influenza (11–13), but the importance of broadly protective immunity remains unclear in this context.

Recent studies have highlighted childhood imprinting's ability to shape multiple layers of influenza immune memory, both broad and narrow. Until recently, relatively narrow cross-protective immunity, which only protects against closely related antigenic variants of the same hemagglutinin (HA) subtype, has been considered the norm. Lymphocyte memory of variable epitopes on the HA head (i.e. sites at which hemagglutinin antigens of different subtypes show limited homology) drives this narrow, within-subtype protection, which is the main mechanism of protection from the inactivated influenza vaccine. But protection may also be driven by memory of other influenza antigens (e.g. neuraminidase, NA) (14–16), or by immune response to conserved epitopes, many of which are found on the HA stalk (10,17–19). Antibodies that target conserved HA epitopes can provide broad protection across multiple HA subtypes in the same phylogenetic group (17,19,20), where HA group 1 contains hemagglutinin subtypes H1 and H2, while group 2 contains H3 (10,18,21). H1, H2 and H3 are the only HA subtypes that have circulated seasonally in humans since 1918.

Within-subtype cross-protection is known to shape seasonal influenza's epidemiology and

evolution (22). But because this type of narrow immunity decays rapidly in the face of antigenic drift, it

would not be expected to shape cohort-specific protection across an entire human lifetime (23,24).

Conversely, broad, HA group-level immune memory arises when lymphocytes target conserved HA

epitopes, and can play a strong role in defense against unfamiliar influenza strains (e.g. novel, avian or

pandemic subtypes (10,17,19,20,25,26)). Broad, HA group-level responses are not traditionally thought to

play a strong role in defense against familiar, seasonal influenza subtypes, but could plausibly be

deployed against drifted seasonal strains whose variable HA epitopes have become unrecognizable.

Because the conserved antigenic targets involved in broad, HA group-level protection are relatively stable

over time, they could in theory, facilitate lifelong imprinting-related biases in immune memory (10,26).

Thus, childhood immune imprinting may determine which birth cohorts are primed for effective defense

against seasonal strains with conserved HA epitopes characteristic of group 1 or group 2, or with variable

HA epitopes characteristic of a particular subtype (H1, H2, etc.). A similar line of reasoning may apply to

immunity against NA, although much less attention has been paid to this antigen.

Since 1977, two distinct subtypes of influenza A, H1N1 and H3N2, have circulated seasonally in

humans, with striking but poorly understood differences in their age-specific impact (8,11–13,27). These

differences could be associated with childhood imprinting: older cohorts were almost certainly exposed to

H1N1 in childhood (since it was the only subtype circulating in humans from 1918-1957), and now seem

to be preferentially protected against modern seasonal H1N1 variants (8,11–13). Likewise, younger adults

have the highest probabilities of childhood imprinting to H3N2, which is consistent with relatively low

incidence of seasonal H3N2 in these cohorts (***Fig. 1-2***). Alternatively, differences in the evolutionary

dynamics of H1N1 and H3N2 could explain the observed age profiles. Subtype H3N2 exhibits slightly

faster drift in its antigenic phenotype than H1N1, and as a result, H3N2 may be more able to escape pre-

existing immunity and infect older, immunologically experienced adults, whereas H1N1 may be relatively

restricted to infecting immunologically naïve children (28).

We analyzed a large data set on seasonal influenza incidence to test whether cohort effects from

childhood imprinting primarily act against variable epitopes, only providing cross-protection against

closely related HA or NA variants of the same subtype, or against more conserved epitopes, providing

broad cross-protection across HA subtypes in the same phylogenetic group (*Fig. 1A-B*). We fitted a suite

of models to data using maximum likelihood and compared models using AIC. In a separate analysis, we

considered the hypothesis that differences in evolutionary rate of H1N1 and H3N2, rather than imprinting

effects, shape differences in age distribution. Our results have implications for long-term projections of

seasonal influenza risk in elderly cohorts (12), who suffer the heaviest burdens of influenza-related

morbidity and mortality, and whose imprinting status will shift through time as cohorts born during

different inter-pandemic eras grow older.

96   **The Data**

The Arizona Department of Health Services (ADHS) provided a dataset containing 9,510

seasonal H1N1 and H3N2 cases from their statewide surveillance system. Cases of all ages were

confirmed to subtype by PCR and/or culture, primarily from virologic testing at the Arizona State Public

Health Laboratory. A smaller number of positive influenza tests were obtained through reporting by other

clinical labs, which has been mandatory in Arizona since 2004 (29). Cases were observed across 22 years

of influenza surveillance, from the 1993-1994 influenza season through the 2014-2015 season, although

sample sizes increased dramatically after the 2009 pandemic (*Table 1*). The data included positive test

results from patients in hospitals, long-term care facilities, correctional facilities, and outpatient clinics,

and thus captured a range of case severities.

Following CDC standards, ADHS defines the influenza season as epidemiological week 40

(around early October) through week 39 of the following year (30). The 2008-2009 and 2009-2010

influenza seasons spanned the first and second wave, respectively, of the 2009 H1N1 pandemic. We did

not analyze cases observed during this time period, because age distributions of infection and molecular

drivers of immune memory differed during the 2009 pandemic from the normal, drivers of seasonal

influenza's immuno-epidemiology of interest to this study (13,17,20). From the dataset of 9,510 seasonal

cases (defined as any case observed outside the 2008-2009 or 2009-2010 season), we excluded 58 cases

with birth years before 1918 (whose imprinting status could not be inferred unambiguously), and one case

whose year of birth was recorded in error. Ultimately, we analyzed 9,541 cases.

The Model

Reconstructed imprinting patterns

We reconstructed birth year-specific probabilities of childhood imprinting to H1N1, H2N2 or

H3N2 using methods described previously (10). These probabilities are based on patterns of first

childhood exposure to influenza A and reflect historical circulation (*Fig. 1A*). Most individuals born

between pandemics in 1918 and 1957 experienced a first influenza A virus (IAV) infection by H1N1, and

middle-aged cohorts born between pandemics in 1957 and 1968 almost all were first infected by H2N2

(note that because the first influenza exposure may occur after the first year of life, individuals born in the

years leading up to a pandemic have some probability of first infection by the new pandemic subtype,

Fig. 1A). Ever since its emergence in 1968, H3N2 has dominated seasonal circulation in humans, and

caused the majority of first infections in younger cohorts. However, H1N1 has also caused some seasonal

circulation since 1977, and has imprinted a fraction of all cohorts born since the mid-1970s (*Fig. 1A*).

Reconstructions assumed children age 0-12 in the year of case observation might not yet have

been exposed to any influenza virus. Interactions between imprinting and vaccination of naïve infants are

plausible, but poorly understood (10,31). We did not consider childhood vaccination effects here; only a

small percentage of individuals in the ADHS data were born at a time when healthy infants were routinely

vaccinated against influenza.

Expected age distributions under alternate imprinting models

If HA subtype-level imprinting protection shapes seasonal influenza risk, primary exposure to HA subtype H1 or H3 in childhood should provide lifelong protection against modern variants of the same HA subtype. If imprinting protection acts primarily against specific NA subtypes, lifelong protection will be specific to N1 or to N2 (*Fig. 1B*). Alternatively, if broad HA group-level imprinting shapes seasonal influenza risk, then cohorts imprinted to HA subtype H1 or H2 (both group 1) should be protected against modern, seasonal H1N1 (also group 1), while only cohorts imprinted to H3 (group 2) would be protected against modern, seasonal H3N2 (also group 2) (*Fig. 1B*). Collinearities between the predictions of different imprinting models (*Fig. 1D-I*) were inevitable, given the limited diversity of influenza antigenic subtypes circulating in humans over the past century (reflected in *Fig. 1A*). Note that middle-aged cohorts, which were first infected by H2N2, are crucial, because they provide the only leverage to differentiate between imprinting at the HA subtype, NA subtype or HA group-level level (*Fig. 1B*).

Our approach distinguishes between age-specific risk factors of influenza infection related to health and social behavior, and birth year-specific effects related to imprinting. Specifically, age-specific risk could be influenced by medical factors like age-specific vaccine coverage, age-specific risk of severe disease, and immunosenescence, or by behavioral factors like age-assorted social mixing, and age-specific healthcare seeking behavior. These factors should have similar impacts on any influenza subtype. In contrast, imprinting effects are subtype-specific. Thus, we fit a step function to characterize the shape of age-specific risk of any confirmed influenza infection. Simultaneously, we modeled residual, subtype-specific differences in risk as a function of birth year, to focus on the possible role of childhood imprinting in H1N1 or H3N2 infections. Each tested model used a linear combination of age-specific risk (*Fig. 1C*) and birth year-specific risk (*Fig. 1D-F*) to generate an expected distribution of H1N1 or H3N2 incidence (*Fig. 1G-I*). Note that for a given birth cohort, age-specific risk changed across progressive years of case observation (as the cohort got older), whereas birth year-specific risk was constant over time.

To test quantitatively whether observed subtype-specific differences in incidence were most

consistent with imprinting at the HA subtype, NA subtype or HA group level, or with no contribution of

imprinting, we fitted a suite of models to each data set using a multinomial likelihood and then performed

model selection using AIC. AIC is used to compare the relative strength of statistical support for a set of

candidate models, each fitted to the same data, and favors parsimonious models that fit the data well

(32,33). Technical details are provided in the *Methods*.

Tested models

We fit a set of four models to the ADHS data set. The simplest model contained only age-specific

risk (abbreviated A), and more complex models added effects from imprinting at the HA subtype level

(S), at the HA group level (G), or at the NA subtype level (N): abbreviated AS, AG, and AN,

respectively. The age-specific risk curve took the form of a step function, in which relative risk was fixed

to 1 in age bin 0-4, and one free parameter was fit to represent relative risk in each of the following 12

age bins: {5-10, 11-17, 18-24, 25-31, 32-38, 39-45, 46-52, 53-59, 60-66, 67-73, 74-80, 81+}. Within

models that contained imprinting effects, two additional free parameters described the relative risk of

confirmed H1N1 or H3N2 infection, given imprinting protection against that seasonal subtype.

Effect of influenza evolutionary rate on age profiles

We used publicly available data from *Nextstrain* (34,35), and from one previously published

study (36), to calculate annual antigenic advance, which we defined as the antigenic distance between

strains of a given lineage (pre-2009 H1N1, post-2009 H1N1 or H3N2) that circulated in consecutive

seasons (*Methods*). The "antigenic distance" between two influenza strains is used as a proxy for

similarity in antigenic phenotype, and potential for immune cross-protection. A variety of methods have

been developed to estimate antigenic distance using serological data, genetic data, or both (35–37).

To assess the impact of antigenic evolutionary rate on the epidemic age distribution, we tested

whether the proportion of cases in children increased in seasons associated with large antigenic changes.

If the rate of antigenic drift is a strong driver of age-specific influenza risk, then the fraction of influenza

cases observed in children should be negatively related to annual antigenic advance (28). In other words,

strains that have not changed much antigenically since the previous season should be unable to escape

pre-existing immunity in immunologically experienced adults, and more restricted to causing cases in

immunologically naïve children; strains that have changed substantially will be less restricted to children.

193   **Results**

Subtype-specific differences in age distribution

Seasonal H3N2 epidemics consistently caused more cases in older cohorts, while H1N1 caused a

greater proportion of cases in young and middle-aged adults (***Figs. 2, S1-S2***). These patterns were

apparent whether we compared H3N2 epidemic age distributions with those caused by the pre-2009

seasonal H1N1 lineage, or with the post-2009 lineage. Observed patterns are consistent with the predicted

effects of cohort-specific imprinting (***Fig. 1***), and with previously reported differences in age distribution

of seasonal H1N1 and H3N2 incidence (11–13,27). See ***Fig. 2*** for seasons where H1N1 and H3N2 co-

circulated in substantial numbers, and ***Figs. S1-S2*** for the entire dataset and alternate smoothing

parameters.

Imprinting model selection

The model containing NA subtype-level imprinting received the most statistical support, and the

model containing HA subtype-level imprinting was the second most preferred in terms of AIC (***Fig. 3,***

Table 2). The ADHS data showed a strong preference for NA subtype-level imprinting over HA subtype-

level imprinting (ΔAIC=23.42), and effectively no statistical support for broad, HA group-level

imprinting (ΔAIC=245.18), or for an absence of imprinting effects (ΔAIC=380.47). Visual assessment of

model fits (***Fig. 3C-D***) confirmed that models containing imprinting effects at the narrow, NA or HA

subtype levels provided the best fits to data. The lack of support for the no-imprinting model supports the

hypothesis that imprinting from the first exposure shapes lifelong seasonal influenza risk, just as it does

avian-origin influenza (10, 12). However, imprinting appears to act more narrowly against seasonal

influenza than against avian influenza, providing cross protection only to a specific NA or HA subtype,

instead of broader, HA group-level protection. This result is consistent with the idea that

immunodominance of variable HA epitopes limits the breadth of immune cross protection deployed

against familiar, seasonal influenza subtypes (19,20).

As expected (see *Fig. 1G-I*), predictions from the two best models were highly collinear, except

in their risk predictions among middle-aged, H2N2-imprinted cohorts (birth years 1957-1968), and some

other minor differences arising from normalization across birth-years.

Fitted risk patterns

Fitted age-specific risk curves took similar forms in all tested models, with risk decreasing

rapidly from birth through adolescence, and then decreasing much more slowly until the end of life (*Fig.*

2A shows the fitted curve from the best model). Estimates of imprinting parameters were less than one,

indicating some reduction in relative risk of infection (*Table 2*). Within the best model, estimated

reductions in relative risk from childhood imprinting were stronger for H1N1 (0.34, 95% CI 0.29-0.42)

than for H3N2 (0.71, 95% CI 0.62-0.82). *Table 2* shows parameter estimates and 95% profile confidence

intervals from all models fitted.

Effect of evolutionary rate

To test for effects of evolutionary rate on epidemic age distribution, we searched for decreases in

the proportion of cases among children in seasons associated with antigenic novelty, when highly drifted

strains might be more able to infect immunologically experienced adults. Consistent with this expectation,

the data showed a slight negative but not significant association between annual antigenic advance and

the fraction of H3N2 cases observed in children (*Fig. 4A*). However, note that no clear relationship

emerged between antigenic novelty and the fraction of cases observed in children and adults older than 10

(*Fig. 4A*). These are the cohorts in which epidemiological data show the clearest differences between

H1N1 and H3N2's age-specific impacts (*Fig. 2*); if rate of antigenic evolution is a dominant driver of

age-specific differences in incidence, we would have expected to see clearer evidence of evolutionary rate

effects within adults cohorts, not just in the youngest children. The data contained too few influenza

seasons with sufficient numbers of confirmed H1N1 cases to support meaningful Pearson correlation

coefficients for either pre-2009 or post-2009 seasonal H1N1 lineages.

Furthermore, if evolutionary rate is the dominant driver of subtype-specific differences in

epidemic age distribution, then when subtypes H1N1 and H3N2 show similar degrees of annual antigenic

advance, their age distributions of infection should appear more similar. However, the data showed that

differences in H1N1 and H3N2's age-specific impacts did not converge when lineages showed similar

annual advance. When comparing the fraction of cases observed in specific age classes, H1N1 data

consistently clustered separately from H3N2, with H1N1 consistently causing fewer cases at the extremes

of age (children 0-10 and elderly adults 71-85), but more cases in middle-aged adults, regardless of

antigenic novelty (*Fig. 4A*). Smoothed density plots showed no clear relationship between annual

antigenic advance and age distribution (*Fig. 4B*). Overall, the data showed a weak, but not significant

signal that incidence may be more restricted to young children when antigenic novelty is low, but the data

did not show strong evidence that the magnitude of annual antigenic drift is a systematic driver of

epidemic age distribution across the entire population.

257   **Discussion**

We analyzed a large epidemiological surveillance dataset and found that seasonal influenza

subtypes H1N1 and H3N2 cause different age distributions of infection, confirming previously reported

patterns (11–13). We analyzed several possible drivers of these differences side-by-side, and found

greatest support for the hypothesis that immunological imprinting leads to lasting protection against the

NA or HA subtype of the first influenza strain encountered in childhood (11,12). The data did not support

strong effects from broader HA group-level imprinting, as recently detected for novel zoonotic or

pandemic viruses (8,10), or from differences in rates of antigenic evolution (28). Our results suggest that

the first childhood infection leaves a lifelong imprint of immune memory to seasonal influenza, and that

this imprint is not erased even after decades of exposure to or vaccination against dissimilar influenza

subtypes.

As additional evidence that birth year, rather than age, drives subtype-specific differences in

seasonal influenza risk, we note that H3N2's impacts have not always been focused in elderly cohorts.

When H3N2 first emerged in 1968, it caused little or no excess mortality in the elderly, putatively

because those who were elderly in 1968 had been exposed, as children or young adults, to an H3 virus

that had circulated in the late 1800s (6,8). Meanwhile, H1N1-imprinted cohorts (those ~10-50 years old at

the time of the H3N2 pandemic), experienced considerable excess mortality in the H3N2 pandemic (6),

and continue to experience excess H3N2 morbidity and mortality today as elderly adults ((11–13,27), **Fig.**

2). In short, comparing data from H3N2's emergence in 1968 to its seasonal circulation today shows

impacts that have remained consistent with respect to birth year, but that have shifted with respect to age.

In model comparison, the data showed the strongest support for effects from childhood imprinting

to NA. Although NA is not as intensively studied as HA, these results emphasize the increasingly

recognized importance of both antigens as drivers of protection against seasonal influenza (14–16).

Realistically, some combination of effects from both HA and NA subtype-level imprinting probably

shape seasonal influenza risk. The models containing NA and HA subtype-level imprinting produced very

similar fits to data and emerged as the top two models in terms of AIC. Unfortunately, collinearities

between predictions of the simple, single-antigen models considered here arose inevitably from

influenza's limited diversity of circulation in humans over the past century. These collinearities prevented

us from testing more complicated models of combined effects from imprinting to HA and NA, or to other

antigens such as internal proteins. Because analysis of population-level data can support only a limited

scope of inference, deeper insights into the respective roles of HA, NA and other influenza antigens as

drivers of cohort effects will most likely need to come from focused immunological cohort studies in

which individual histories of influenza infection are known, such as those recently funded by the National

Institutes of Health (38). Alternatively, the development of immunological biomarkers for diagnosis of

imprinting status in individual patients could substantially increase the power of epidemiological

inference, which (as in this study) currently relies instead on probabilistic reconstructions of imprinting

histories according to birth year.

Small sample sizes may have limited our power to detect a statistically significant relationship

between annual antigenic advance and epidemic age distribution. The data did show a weak trend

supporting the idea that in seasons where antigenic advance is low, the seasonal influenza cases may be

more restricted to the youngest, immunologically naïve children (28). But the data did not reveal a clear

relationship between antigenic advance and the fraction of cases occurring in adult age groups, the same

age groups where epidemiological data reveals distinct subtype-specific differences in incidence

proportion. This lack of clear signal is consistent with growing recognition that existing methods to map

antigenic distance, which rely heavily on hemagglutination inhibition (HI) assays performed in laboratory

ferrets, do not always capture realistic patterns of cross-reactivity in humans (reviewed in 39,40). Further,

glycosylation of HA can cause antigenic escape in large subsets of the human population, yet such

posttranslational modifications may be perceived as neutral in existing antigenic maps (40,41). Moreover,

existing metrics of evolutionary and antigenic advance are based on properties of HA (34–36), but our

epidemiologic data support an equal if not stronger role of NA. We speculate that a clearer relationship

between epidemic age distribution and antigenic drift might emerge if antigenic distance measures were

able to incorporate cohort-specific variation in immune history, and impacts from multiple antigens.

While our results provide some valuable new clues about the underlying immune drivers of

imprinting protection against seasonal influenza, we can only speculate as to the exact mechanism.

Traditionally, narrow, within-subtype influenza immunity is thought to decay quickly in the face of

antigenic drift. Signals of rapid drift are largely based on HI data, which measures antibody responses to

just a handful of immunodominant, variable epitopes found near the receptor-binding domain on the HA

head. These epitopes accumulate substitutions rapidly, and so strains that circulated more than 14 years

apart rarely show measurable cross-protective HI titers (36). The short timescale of immune memory to

variable HA head epitopes stands in contrast to patterns observed in our study and others (11–13), where

within-subtype immune memory imprinted in childhood appears to persist for an entire human lifetime,

remaining evident even in the oldest cohorts in the data. Thus, we speculate that within-subtype

imprinting protection arises via different immune mechanisms than the well-studied antibody responses

measured by the HI assay.

One possibility is that within-subtype imprinting protection is driven by antibody responses to

intermediately conserved epitopes, which might remain stable over time, but lack structural homology

across different HA and NA subtypes. We rule out a strong role from antibody responses against the best-

studied conserved epitopes (e.g. those on the stalk), which tend to provide broader, cross-subtype

protection (10,17,19) than supported by model comparison. But recent studies show that B cell memory

shifts to focus on conserved influenza epitopes as we grow older, presumably because a lifetime of

exposures to drifted, seasonal H1N1 or H3N2 variants repeatedly back-boosts memory of unchanged

epitopes (23,24). Repeat boosting of intermediately conserved HA or NA antigens could explain the

longevity of subtype-level imprinting protection.

Another potential explanation supported by recent immunological data (26), is that the memory B

cell clones developed during the first childhood influenza exposure later adapt via somatic hypermutation

to "follow" antigenic targets as they drift over time. Thus, the first influenza exposure in life may fill a

child's memory B cell repertoire with clones that will serve in the future, not as final products but as

prototypes that can be rapidly and effectively tailored to recognize drifted influenza strains of the same

subtype. The adaptability of the B cell repertoire would not be detectable in traditional HI panels, which

are collected using sera from ferrets exposed to a single influenza variant, and do not reflect the

development of the human B cell repertoire across repeated, seasonal influenza exposures. A final

possibility is that cellular immunity (e.g. CD4+ T cell memory), which would not be captured in

serological assays, plays an underappreciated role in imprinting protection.

Signals of imprinting protection are anomalously strong in the current cohort of elderly adults, as

reflected by higher estimates of imprinting protection to H1N1 than H3N2. For nearly four decades from

1918-1957, H1N1 persisted as the only strain circulating in humans. The oldest subjects in our data were

born slightly after its emergence in 1918, and would not have encountered an influenza virus of any

subtype but H1N1 until after age 30. Decades of early-life exposures to H1N1 variants may have

reinforced and expanded the breadth of H1N1-specific immune memory in these oldest cohorts. But this

strong protection against H1N1 seems to come at a cost; even after decades of seasonal H3N2 exposure,

and vaccination, older cohorts have evidently failed to develop equally strong protection against H3N2.

Antigenic similarity between H1N1 strains that circulated earlier in the 20th century (which caused

imprinting in older cohorts), and modern H1N1 lineages that emerged in 1977 and in 2009, may also have

amplified the strength and longevity of H1N1 protection (4,42). One additional consideration is that HA

group 1 antigens appear to induce narrower immune responses than structurally distinct HA group 2

antigens, which may be better able to induce cross-group responses (21). Perhaps elderly cohorts

imprinted to group 1 antigens have been trapped in narrower responses that offer exceptional protection

against strains similar to that of first exposure but relatively poor adaptability to other subtypes.

Given that cohorts born after 1968 have had much more varied early life exposures to both H1N1

and H3N2, it is unclear whether equally strong, subtype-specific biases in protection will persist when

post-1968 birth cohorts eventually become elderly. Determining the precise immune mechanism(s)

responsible for subtype-level imprinting is necessary to project long-term shifts in influenza-related

incidence, and possibly in mortality. The vast majority of influenza-related deaths occur in adults over

age 65, and H3N2 has caused many times the number of fatalities in high-risk elderly cohorts as seasonal

H1N1, even in the post-2009 pandemic period (12,27,43). These patterns may arise because H3N2 is

intrinsically more virulent than H1N1, but we speculate that imprinting protection, which currently limits

the incidence of clinically-attended H1N1 infection in the elderly, may also explain these differences. In

the future, cohorts imprinted to H2N2 (born c. 1950-1968) will become elderly, and would expect

protection against H3N2 via NA subtype-level imprinting, while HA H2-level imprinting would not be of

much use against any currently circulating seasonal subtype. If future elderly cohorts continue to show

strong subtype-specific biases from imprinting, our results would corroborate the idea that mortality from

H1N1 may increase in the future (8,12) as protection in the elderly shifts toward other subtypes. On the

other hand, future generations of elderly adults, especially those born after H1N1 and H3N2 began to co-

circulate in 1977, may show a greater ability to act as immunological generalists, with effective defenses

against multiple influenza subtypes.

One limitation of this study was that we could not model the impact of seasonal influenza

vaccination explicitly, as the vaccination status of subjects in the ADHS data was unknown. We note that

the influenza vaccine contains both an H1N1 and H3N2 strain, and so on average, influenza vaccination

should protect individuals similarly against both subtypes. However, we also acknowledge that influenza

vaccine effectiveness varies by season, age group, and subtype, in ways that are poorly understood and

difficult to measure (44). These asynchronous and multi-dimensional shifts in vaccine effectiveness may

contribute to variability in H1N1 and H3N2's age distributions across influenza seasons.

Another limitation of this study was the low number of confirmed cases available in the pre-2009

era. To separate age-specific risk effects from birth year-specific cohort effects, the greatest power will

come from large data sets collected continuously over decades, so that individual birth cohorts can be

followed as they become considerably older. We emphatically echo earlier calls (45) for more systematic

sharing of single year-of-age in influenza surveillance data, standardization of sampling effort, and

reporting of age-specific denominators, which could substantially boost the scientific community's ability

to link influenza's genetic and antigenic properties with epidemiological outcomes.

Altogether, this analysis confirms that the epidemiological burden of H1N1 and H3N2 is shaped

by cohort-specific differences in childhood imprinting (8,11,12,46). The finding that such imprinting acts

at the HA or NA subtype level informs prediction of the future epidemiological impact of specific

seasonal subtypes in high-risk elderly cohorts. The lack of support for broader, HA group-level imprinting

effects emphasizes the consequences of immunodominance of influenza's most variable epitopes, and the

difficulty of deploying broadly protective memory B cell responses against familiar, seasonal strains.

Overall, these findings further our understanding of how antigenic seniority shapes cohort-specific risk

during epidemics. The fact that elderly cohorts show relatively weak immune protection against H3N2,

even after living through decades of seasonal exposure to or vaccination against H3N2, suggests that

antibody responses acquired in adulthood do not provide the same strength of immune protection as

responses primed in childhood. Immunological experiments that consider multiple viral exposures, and

cohort studies in which individual histories of influenza infection are tracked from birth, promise to

illuminate how B cell and T cell memory develop across a series of early life exposures. In particular,

these studies may provide clearer insights than epidemiological data into which influenza antigens,

epitopes and immune effectors play the greatest role in immune imprinting, and how quickly subtype-

specific biases become entrenched across the first or the first few exposures.

Methods

Estimation of age from birth year in ADHS data

The data contained three variables, influenza season, birth year and confirmed subtype. For most

cases, birth year was extracted directly from the reported date of birth in patient medical records, but age

was not known. We estimated patient age at the time case observation using the formula [year of

observation]-[birth year]. To ensure that the minimum estimated age was 0, the second year in the

influenza season of case observation was considered the calendar year of observation (e.g. 2013 for the

2012-2013 season).

Splines

In *Figure 2*, smoothing splines were fit to aid visual interpretation of noisy data. We fit splines

using the command *smooth.spline(x = AGE, y = FRACTIONS, spar = 0.8)* in R version 3.5.0. Variables

AGE and *FRACTIONS* were vectors whose entries represented single years of age, and the fraction of

cases observed in the corresponding age group. The smoothing parameter 0.8 was chosen to provide a

visually smooth fit. Alternative smoothing parameter choices (0.6 & 1.0) are shown in **Figs. S1-S2**.

Although the choice of smoothing parameter changed the shape of each fitted spline, qualitative

differences between splines fitted to H1N1 or H3N2 were robust.

Model formulation

For each unique season in which cases were observed, define p as a vector whose entries

represent the expected probability that a randomly drawn H1N1 or a randomly drawn H3N2 case was

observed in an individual of age a. Each model defined, p as a linear combination of age-specific risk,

birth year-specific risk (i.e. imprinting effects). All tested models were nested within the equation:

$$p = A * \mathbf{1}_{H1N1}(I_{H1N1}) * \mathbf{1}_{H3N2}(I_{H3N2}) \hspace{4cm} \textbf{1}$$

To include risk factors that only modulated risk from one subtype, we included indicator

functions $\mathbf{1}_{H1N1}$ and $\mathbf{1}_{H3N2}$, which took value 1 if p described the expected age distribution of H1N1 or

H3N2 cases, respectively, and 0 otherwise.

Age-specific risk (A)

Age-specific risk was defined as a step function, in which relative risk was fixed to value 1 in an

arbitrarily chosen age bin, and then z-1 free parameters, denoted r_2 to r_z, were fit to describe relative risk

in all other age bins. Below, $\mathbf{1}_i$ are indicator functions specifying whether each vector entry is a member

of age bin i. To obtain the predicted fraction of cases observed in each single year of age, we normalized

the risk distribution so that predicted risk across all age groups summed to 1.

$$A = norm(\mathbf{1}_1 + \mathbf{1}_2 r_2 + \cdots \mathbf{1}_z r_z) \hspace{4cm} \textbf{2}$$

Imprinting (I)

An indicator function defined whether a given prediction vector described risk of confirmed

H1N1 or H3N2 infection. Let f_{IHxNy} be vectors describing the fraction of cases of each birth year that were

protected against strain $HxNy$ by their childhood imprinting. We defined r_{IHxNy} as free parameters

describing the risk of confirmed $HxNy$ infection, given imprinting protection. Finally, the factor

describing the effect of imprinting (I) was defined as:

$$I_{HxNy} = \mathbf{1}_{HxNy} * [f_{IHxNy}r_{IHxNy} + (1 - f_{IHxNy})] \qquad\qquad \mathbf{3}$$

Likelihood

We used equations 1-3 to generate predicted case age distributions (p) for each influenza season

(s) in which cases were observed in the data. Then, the likelihood was obtained as a product of

multinomial densities across all seasons. If n_s represents the total number of cases observed in a given

season, $x_{0cs},...x_{mcs}$ each represent the number of cases observed in each single year of age/single year of

birth, and if $p_{0cs}...p_{mcs}$ each represent entries in the model's predicted age/birth year-distribution of cases,

then the likelihood is given by:

$$\mathcal{L} = \prod_{s} \frac{n_s!}{x_{0s}!...x_{ms}!} p_{0s}^{x_{0s}} ... p_{ms}^{x_{ms}} \qquad\qquad \mathbf{4}$$

Model fitting and model comparison

We fit models containing all possible combinations of the above factors to influenza data from

each season in the data. We simultaneously estimated all free parameter values using the optim() function

in R. We calculated likelihood profiles and 95% profile confidence intervals for each free parameter.

Confidence intervals were defined using the method of likelihood ratios (32).

Antigenic advance

We obtained antigenic distance estimates from *Nextstrain (nextstrain.org)*(34,47)*, and from

source data from Figure 3 in Bedford et al. (36). *Nextstrain* calculates antigenic distance using genetic

data from GISAID (48), and using methods described by Neher et al. (35). We analyzed "CTiter"

estimates from *Nextstrain*, which correspond to Neher et al.'s "tree model" method. We repeated analyses

using estimates from the similar "substitution model" method and verified that our choice of antigenic

distance metric did not meaningfully impact our results (results not shown). Datasets from *Nextstrain* and

Bedford et al. both contained redundant antigenic distance estimates for the H3N2 lineage, but only

Bedford et al. analyzed the pre-2009 H1N1 lineage, and only *Nextstrain* data analyzed the post-2009

H1N1 lineage. The antigenic distance estimates reported by Bedford et al. were roughly proportional to

those reported on *Nextstrain*, but greater in absolute magnitude (35). To enable visualization of all three

lineages on the same plot axes, we rescaled pre-2009 H1N1 estimates from Bedford et al. using the

formula $d_{Nextstrain} = 0.47 d_{Bedford}$. The scaling factor was chosen so that directly-comparable H3N2 distance

estimates obtained using each method spanned the same range (***Fig. S3***). The *Nextstrain* data files used in

this analysis are archived within our analysis code.

References

484   1.   Francis T. On the Doctrine of Original Antigenic Sin. Proc Am Philos Soc. 1960;104(6):572–8.

485   2.   Lessler J, Riley S, Read JM, Wang S, Zhu H, Smith GJD, et al. Evidence for Antigenic Seniority in
486   Influenza A (H3N2) Antibody Responses in Southern China. PLOS Pathog. 2012 Jul
487   19;8(7):e1002802.

488   3.   Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA. Structural Basis of Preexisting Immunity
489   to the 2009 H1N1 Pandemic Influenza Virus. Science. 2010 Apr 16;328(5976):357–60.

490   4.   Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-Reactive Antibody
491   Responses to the 2009 Pandemic H1N1 Influenza Virus. N Engl J Med Boston. 2009 Nov
492   12;361(20):1945–52.

493   5.   Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global
494   Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling
495   Study. PLOS Med. 2013 Nov 26;10(11):e1001558.

496   6.   Simonsen L, Reichert TA, Miller MA. The virtues of antigenic sin: consequences of pandemic
497   recycling on influenza-associated mortality. Int Congr Ser. 2004 Jun 1;1263:791–4.

498   7.   Ma J, Dushoff J, Earn DJD. Age-specific mortality risk from pandemic influenza. J Theor Biol.
499   2011 Nov 7;288:29–34.

500   8.   Worobey M, Han G-Z, Rambaut A. Genesis and pathogenesis of the 1918 pandemic H1N1
501   influenza A virus. Proc Natl Acad Sci. 2014 Jun 3;111(22):8107–12.

502   9.   Gagnon A, Miller MS, Hallman SA, Bourbeau R, Herring DA, Earn DJD, et al. Age-Specific
503   Mortality During the 1918 Influenza Pandemic: Unravelling the Mystery of High Young Adult
504   Mortality. PLoS ONE [Internet]. 2013 Aug 5 [cited 2019 Apr 4];8(8). Available from:
505   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734171/

506   10.   Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1 and H7N9
507   influenza via childhood hemagglutinin imprinting. Science. 2016 Nov 11;354(6313):722–6.

508   11.   Khiabanian H, Farrell GM, George KS, Rabadan R. Differences in Patient Age Distribution
509   between Influenza A Subtypes. PLOS ONE. 2009 Aug 31;4(8):e6832.

510   12.   Budd AP, Beacham L, Smith CB, Garten RJ, Reed C, Kniss K, et al. Birth Cohort Effects in
511   Influenza Surveillance Data: Evidence that First Influenza Infection Affects Later Influenza-
512   Associated Illness. J Infect Dis [Internet]. [cited 2019 May 20]; Available from:
513   https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiz201/5485579

514   13.   Lemaitre M, Carrat F. Comparative age distribution of influenza morbidity and mortality during
515   seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infect Dis. 2010 Jun 9;10(1):162.

516   14.   Huang QS, Bandaranayake D, Wood T, Newbern EC, Seeds R, Ralston J, et al. Risk Factors and
517   Attack Rates of Seasonal Influenza Infection: Results of the Southern Hemisphere Influenza and
518   Vaccine Effectiveness Research and Surveillance (SHIVERS) Seroepidemiologic Cohort Study. J
519   Infect Dis. 2019 Jan 9;219(3):347–57.

520   15.   Cowling BJ, Sullivan SG. The Value of Neuraminidase Inhibition Antibody Titers in Influenza
521   Seroepidemiology. J Infect Dis. 2019 Jan 9;219(3):341–3.

522   16.   Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, et al. Evaluation of
523   Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza
524   A/H1N1 Virus Healthy Human Challenge Model. mBio [Internet]. 2016 Apr 19 [cited 2019 May
525   31];7(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959521/

526   17.   Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-
527   reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza
528   virus infection. J Exp Med. 2011 Jan 17;208(1):181–93.

529   18.   Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, et al. Hemagglutinin stalk antibodies
530   elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1
531   viruses. Proc Natl Acad Sci U S A. 2012;109(7):2573–8.

532   19.   Krammer F. Novel universal influenza virus vaccine approaches. Curr Opin Virol. 2016 Apr;17:95–
533   103.

534   20.   Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, et al. Immune history profoundly
535   affects broadly protective B cell responses to influenza. Sci Transl Med. 2015 Dec
536   2;7(316):316ra192-316ra192.

537   21.   Zost SJ, Wu NC, Hensley SE, Wilson IA. Immunodominance and Antigenic Variation of Influenza
538   Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. J Infect Dis.
539   2019 Apr 8;219(Supplement_1):S38–45.

540   22.   Grenfell BT, Pybus OG, Gog JR, Wood JLN, Daly JM, Mumford JA, et al. Unifying the
541   Epidemiological and Evolutionary Dynamics of Pathogens. Science. 2004 Jan 16;303(5656):327–
542   32.

543   23.   Henry C, Zheng N-Y, Huang M, Cabanov A, Rojas KT, Kaur K, et al. Influenza Virus Vaccination
544   Elicits Poorly Adapted B Cell Responses in Elderly Individuals. Cell Host Microbe. 2019
545   Mar;25(3):357-366.e6.

546   24.   Age-specific differences in the dynamics of protective immunity to influenza | Nature
547   Communications [Internet]. [cited 2019 May 6]. Available from:
548   https://www.nature.com/articles/s41467-019-09652-6

549   25.   Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, et al. Neutralizing
550   Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A
551   Longitudinal Analysis. Sci Transl Med. 2013 Aug 14;5(198):198ra107-198ra107.

552   26.   Tesini BL, Kanagaiah P, Wang J, Hahn M, Halliley JL, Chaves FA, et al. Broad Hemagglutinin-
553   Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life
554   Imprinting and Adaptation to the Infecting Virus. J Virol. 2019 Apr 15;93(8):e00169-19.

555   27.   Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality
556   associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan
557   8;289(2):179–86.

558   28.   Bedford T, Riley S, Barr IG, Broor S, Chadha M, Cox NJ, et al. Global circulation patterns of
559   seasonal influenza viruses vary with antigenic drift. Nature. 2015 Jul;523(7559):217–20.

560   29.   Arizona Department of Health Services. 2015–2016 Influenza Summary [Internet]. [cited 2019 May
561   23]. Available from: https://www.azdhs.gov/documents/preparedness/epidemiology-disease-
562   control/flu/surveillance/2015-2016-influenza-summary.pdf

563   30.   National Notifiable Diseases Surveillance System, Division of Health Informatics and Surveillance,
564   National Center for Surveillance, Epidemiology and Laboratory Services. MMWR Week Fact Sheet
565   [Internet]. [cited 2019 May 23]. Available from:
566   https://wwwn.cdc.gov/nndss/document/MMWR_Week_overview.pdf

567   31.   Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, et al. A Universal
568   Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.
569   J Infect Dis. 2018 Jul 2;218(3):347–54.

570   32.   Bolker BM. Ecological Models and Data in R. Princeton University Press; 2008. 409 p.

571   33.   Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical Information-
572   Theoretic Approach [Internet]. 2nd ed. New York: Springer-Verlag; 2002 [cited 2019 Apr 16].
573   Available from: https://www.springer.com/us/book/9780387953649

574   34.   Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time
575   tracking of pathogen evolution. Bioinformatics. 2018 Dec 1;34(23):4121–3.

576   35.   Neher RA, Bedford T, Daniels RS, Russell CA, Shraiman BI. Prediction, dynamics, and
577   visualization of antigenic phenotypes of seasonal influenza viruses. Proc Natl Acad Sci. 2016 Mar
578   22;113(12):E1701–9.

579   36.   Bedford T, Suchard MA, Lemey P, Dudas G, Gregory V, Hay AJ, et al. Integrating influenza
580   antigenic dynamics with molecular evolution. Losick R, editor. eLife. 2014 Feb 4;3:e01914.

581   37.   Smith DJ, Lapedes AS, Jong JC de, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, et al.
582   Mapping the Antigenic and Genetic Evolution of Influenza Virus. Science. 2004 Jul
583   16;305(5682):371–6.

584   38.   RFA-AI-18-010: Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial
585   Not Allowed) [Internet]. [cited 2019 Apr 15]. Available from:
586   https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-18-010.html

587   39.   Morris DH, Gostic KM, Pompei S, Bedford T, Łuksza M, Neher RA, et al. Predictive Modeling of
588   Influenza Shows the Promise of Applied Evolutionary Biology. Trends Microbiol. 2018 Feb
589   1;26(2):102–18.

590   40.   Cobey S, Hensley SE. Immune history and influenza virus susceptibility. Curr Opin Virol. 2017 Feb
591   1;22:105–11.

592   41.   Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, et al. Potential antigenic
593   explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014
594   influenza season. Proc Natl Acad Sci. 2014 Nov 4;111(44):15798–803.

595   42.   Rozo M, Gronvall GK. The Reemergent 1977 H1N1 Strain and the Gain-of-Function Debate. mBio.
596   2015 Sep 1;6(4):e01013-15.

597   43.   Dushoff J, Plotkin JB, Viboud C, Earn DJD, Simonsen L. Mortality due to Influenza in the United
598   States—An Annualized Regression Approach Using Multiple-Cause Mortality Data. Am J
599   Epidemiol. 2006 Jan 15;163(2):181–7.

600   44.   Lewnard JA, Cobey S. Immune History and Influenza Vaccine Effectiveness. Vaccines. 2018
601   Jun;6(2):28.

602   45.   Gagnon A, Acosta E, Miller MS. Reporting and evaluating influenza virus surveillance data: An
603   argument for incidence by single year of age. Vaccine. 2018 Oct 8;36(42):6249–52.

604   46.   Glezen WP, Keitel WA, Taber LH, Piedra PA, Clover RD, Couch RB. Age Distribution of Patients
605   with Medically-Attended Illnesses Caused by Sequential Variants of Influenza A/H1N1:
606   Comparison to Age-Specific Infection Rates, 1978–1989. Am J Epidemiol. 1991 Feb 1;133(3):296–
607   304.

608   47.   Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. Virus
609   Evol [Internet]. 2018 Jan 8 [cited 2019 Apr 12];4(1). Available from:
610   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758920/

611   48.   Bogner P, Capua I, Lipman DJ, Cox NJ. A global initiative on sharing avian flu data. Nature. 2006
612   Aug;442(7106):981.

Code and data availability

Code to perform all reported analyses and construct all plots is included as a supplementary file. All data is available in the supplementary materials.

Acknowledgements

We are grateful to Ken Komatsu and Kristen Herrick for their assistance with data access, and to Trevor Bedford for assistance accessing and interpreting antigenic distance data from *Nextstrain*. We thank Lone Simonsen for helpful discussions. KG was supported by the National Institutes of Health (F31AI134017, T32-GM008185). JLS was supported by NSF grants OCE-1335657 and DEB-1557022, SERDP RC-2635, and DARPA PREEMPT D18AC00031. MW was supported by the David and Lucile Packard Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclaimer

This work does not necessarily represent the views of the US government or the NIH.

Competing interests

The authors declare no competing interests.

Ethics Statement

This study analyzed only existing epidemiological data, which did not include identifying patient details.

Author contributions

MW, KG and JLS conceived of the questions and modeling analysis. CV and MW provided crucial assistance with data access and study design. SB and RB supervised data curation and advised the modeling arm of our team about compatibility between the data and analysis strategy. KG wrote the code and performed analyses, with supervision from JLS, and drafted the manuscript. All authors provided input on analysis and interpretation of the results, and helped revise and edit the manuscript text.

Figures

Figure 1. Model and expectations under different imprinting hypotheses. (A) Reconstructed, birth year-specific probabilities of imprinting (representative example specific to USA for cases observed in 2015). Throughout the manuscript, group 1 HA subtypes are represented in blue and group 2 subtypes in red. **(B)** Expected imprinting protection against H1N1 or H3N2 under the three tested models. **(C)** Cartoon of age-specific risk curve. The shape of this curve is purely hypothetical, but each tested model fit a similar step function to data. **(D-F)** Fraction of each birth year unprotected by their childhood imprinting (from A) determines the shape of birth year-specific risk. **(G-I)** A linear combination of age-specific risk (C), and birth year-specific risk (D-F) give the expected age distribution of H1N1 or H3N2 cases under each model.

648
649 **Figure 2. Observed age distributions, Arizona**. Points show fraction of confirmed H1N1 or H3N2 cases
650 observed in each single year of age. Lines show a smoothing spline fit to observed distributions. **(A)** All
651 confirmed cases in the data (aggregate across all seasons). **(B-G)** Age distributions from individual
652 seasons in which both H1N1 and H3N2 circulated (seasons with ≥ 50 confirmed cases of each subtype are
653 shown here. See Fig. S1 for all seasons).
654

655
656 **Figure 3**. **Model fits and model selection**. **(A)** Fitted effects of age and **(B)** imprinting from model AN,
657 which provided the best fit to data. **(C-D)** Model fits to observed age distributions of H1N1 **(C)** and
658 H3N2 **(D)** cases. Model name abbreviations indicate which factors were included: A = age-specific risk,
659 N = NA subtype-level imprinting, S = HA subtype-level imprinting, G = HA group-level imprinting.
660

Figure 4. Effect of antigenic advance on age distribution. (A) Relationship between annual antigenic advance and the fraction of cases observed in children (0-10), or in adult age groups. Each data point represents a single influenza season in which at least 100 confirmed cases of a given subtype were observed. Blue label shows Pearson correlation between the fraction of H3N2 cases observed in each age group and annual antigenic advance. Blue dashes show linear trend fitted using lm() in R. **(B)** Season-specific age distributions of infection, colored by antigenic advance since the previous season.

669 # Tables

670 **Table 1. Confirmed cases in surveillance data from Arizona Department of Health Services.** Data
671 representing the first and second waves of the 2009 H1N1 pandemic (2008-2009 and 2009-2010 seasons)
672 were excluded.

Season	Confirmed H1N1	Confirmed H3N2
1993-94	0	101
1994-95	12	38
2002-03	71	8
2003-04	0	71
2004-05	0	131
2005-06	1	321
2006-07	212	28
2007-08	196	244
2010-11	472	1204
2011-12	595	348
2012-13	80	1578
2013-14	1475	151
2014-15	5	2109
Total	**3119**	**6332**

Table 2. Maximum likelihood parameter estimates and 95% profile confidence intervals from each model fit to ADHS data. All estimated parameters represent the relative risk of confirmed infection, given the factors listed in the left-hand column. Model name abbreviations specific which factors were included. A = age-specific risk, N = NA subtype-level imprinting, S = HA subtype-level imprinting, G = HA group-level imprinting.

Model	AN	AS	AG	A
ΔAIC	0.00	23.42	245.18	380.47
H1N1 impr. protection	0.34 (0.29-0.42)	0.29 (0.24-0.35)	0.67 (0.58-0.78)	
H3N2 impr. protection	0.71 (0.62-0.82)	0.9 (0.78- >1)	0.69 (0.6-0.8)	
Ages 0-4	Reference group: Value fixed to 1			
Ages 5-10	0.68 (0.63-0.74)	0.66 (0.61-0.72)	0.66 (0.62-0.72)	0.62 (0.57-0.68)
Ages 11-17	0.33 (0.3-0.36)	0.31 (0.28-0.34)	0.33 (0.3-0.37)	0.3 (0.28-0.34)
Ages 18-24	0.38 (0.35-0.42)	0.36 (0.32-0.4)	0.39 (0.35-0.43)	0.35 (0.32-0.39)
Ages 25-31	0.34 (0.32-0.38)	0.33 (0.3-0.37)	0.34 (0.31-0.38)	0.31 (0.28-0.35)
Ages 32-38	0.28 (0.26-0.32)	0.26 (0.24-0.3)	0.28 (0.26-0.32)	0.26 (0.24-0.29)
Ages 39-45	0.23 (0.2-0.27)	0.21 (0.18-0.24)	0.24 (0.22-0.28)	0.21 (0.2-0.24)
Ages 46-52	0.24 (0.22-0.28)	0.21 (0.19-0.24)	0.24 (0.22-0.28)	0.23 (0.2-0.26)
Ages 53-59	0.22 (0.2-0.26)	0.2 (0.18-0.23)	0.2 (0.18-0.24)	0.2 (0.18-0.23)
Ages 60-66	0.21 (0.19-0.24)	0.22 (0.2-0.26)	0.19 (0.16-0.22)	0.18 (0.16-0.21)
Ages 67-73	0.22 (0.2-0.26)	0.25 (0.22-0.29)	0.2 (0.18-0.23)	0.19 (0.18-0.22)
Ages 74-80	0.23 (0.2-0.26)	0.25 (0.22-0.3)	0.2 (0.18-0.24)	0.2 (0.18-0.23)
Ages 81+	0.15 (0.14-0.18)	0.17 (0.15-0.2)	0.13 (0.12-0.16)	0.13 (0.12-0.15)

Supplementary Figures

Figure S1. ADHS age distributions, all seasons. Supplement to *Fig. 2* showing observed age distributions from all influenza seasons. Observed case fractions (points) were only plotted if 10 or more cases of a given subtype were confirmed, to avoid extreme stretching of the y axis. Smoothing splines were only plotted if 50 or more cases of a given subtype were observed, as fits to fewer data points would not have been meaningful.

688
689 **Figure S2. Alternate smoothing parameters, AZDHS data.** Supplement to *Fig. 2*, with smoothing
690 parameters chosen to fit splines that are less (**A-F**), or more (**G-L**) smooth than the splines shown in the
691 main text. Differences between H1N1 and H3N2's age-specific impacts remain evident, especially in the
692 oldest cohorts, regardless of smootness.
693

694
Figure S3. Comparison of rescaled antigenic distance estimates from the Bedford et al., and
Nextstrain **datasets.** Points represent average antigenic position of all isolates from a given calendar year.